Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms Trastuzumab-TCO-DOTA(TagWorks), TGW 211, TGW211 |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | Netherlands | 01 Nov 2024 | |
Stomach Cancer | Preclinical | Netherlands | 01 Nov 2024 |